# Hepatocellular Carcinoma (HCC)

> Hepatocellular carcinoma (HCC) is a **primary malignancy of hepatocytes**, most commonly arising in the setting of **chronic liver disease or cirrhosis** (e.g., HBV, HCV, NASH, alcohol).

## Space-Occupying Lesions (SOLs) of Liver

> Space-occupying lesions (SOLs) of the liver refer to any **mass lesions**—benign or malignant—that replace normal liver parenchyma and may present with symptoms due to **mass effect** or **compromised liver function**.

<details>
<summary>Classification of Liver SOLs</summary>

### I. Benign Lesions

#### A. Epithelial

1. Hepatocellular adenoma
2. Focal nodular hyperplasia (FNH)
3. Bile duct adenoma
4. Cystadenoma

#### B. Non-Epithelial

1. Hemangioma (most common benign SOL)
2. Lymphangioma
3. Mesenchymal hamartoma

#### C. Cystic Lesions

1. Simple hepatic cyst
2. Hydatid cyst _(caused by Echinococcus granulosus)_
3. Polycystic liver disease
4. Biliary cystadenoma

### II. Malignant Lesions

#### A. Primary Liver Malignancy

1. Hepatocellular carcinoma (HCC)
2. Cholangiocarcinoma
3. Combined HCC–Cholangiocarcinoma
4. Hepatoblastoma _(in children)_
5. Angiosarcoma

#### B. Secondary (Metastatic) Lesions

- Most common malignant liver SOL
- Common primary sites:
  - Colon
  - Breast
  - Lung
  - Pancreas
  - Stomach

### III. Infective/Inflammatory Lesions

1. Pyogenic liver abscess
2. Amoebic liver abscess _(Entamoeba histolytica)_
3. Fungal abscess
4. Tuberculous granuloma

### IV. Miscellaneous

1. Post-traumatic hematoma
2. Regenerative nodules (e.g., in cirrhosis)
3. Sarcoidosis

</details>

## Barcelona Clinic Liver Cancer (BCLC) Staging of HCC

| Stage                | Tumor Features                             | Performance Status (ECOG) | Liver Function | Treatment Options                                 | Median Survival |
| -------------------- | ------------------------------------------ | ------------------------- | -------------- | ------------------------------------------------- | --------------- |
| **0 (Very early)**   | Single lesion < 2 cm, no vascular invasion | 0                         | Child-Pugh A   | Surgical resection or ablation                    | >60 months      |
| **A (Early)**        | ≤3 nodules, each ≤3 cm, no invasion        | 0                         | Child-Pugh A–B | Resection, ablation, or liver transplantation     | 36–60 months    |
| **B (Intermediate)** | Multinodular disease, no vascular invasion | 0                         | Child-Pugh A–B | Transarterial chemoembolization (TACE)            | 20 months       |
| **C (Advanced)**     | Portal invasion, N1, or M1                 | 1–2                       | Child-Pugh A–B | Systemic therapy (e.g., sorafenib, immunotherapy) | 6–11 months     |
| **D (Terminal)**     | Any tumor status                           | >2 or Child-Pugh C        | Child-Pugh C   | Best supportive care                              | 3–6 months      |

## Investigation

### 1. History

- Risk factors: Chronic hepatitis B/C, alcohol, NASH, cirrhosis
- Symptoms: RUQ pain, weight loss, early satiety, jaundice, cachexia

### 2. Physical Examination

- Hepatomegaly
- Ascites
- Icterus
- Palmar erythema, spider nevi
- Signs of decompensated cirrhosis

### 3. Laboratory

- LFTs, PT/INR, CBC, Renal function
- **Alpha-fetoprotein (AFP)** (>400 ng/mL suggests HCC)
- Viral markers: **HBsAg**, **Anti-HCV**

### 4. Imaging

- **Triple-phase contrast-enhanced CT or MRI**
  - Arterial phase enhancement + portal venous washout = diagnostic
- **Ultrasound** (screening tool in cirrhotics)
- **PET scan** (metastasis evaluation)

## Management Based on BCLC Stage

### 1. BCLC Stage 0–A (Very Early / Early Stage)

**Curative Treatment Options**

1. `Surgical resection`
   - Indication: Single lesion, preserved liver function (Child A), no portal hypertension
1. `Liver transplantation`
   - Indication: Within **Milan criteria**:
     - Single lesion ≤5 cm or up to 3 lesions all ≤3 cm
     - No vascular invasion or extrahepatic spread
1. **Local ablation**
   - `Radiofrequency ablation (RFA)` or `microwave ablation`
   - Indicated for unresectable small tumors

### 2. BCLC Stage B (Intermediate Stage)

- `Transarterial chemoembolization (TACE)`
  - Indicated for multinodular, unresectable HCC without vascular invasion or metastasis
  - Drug + embolic agent injected into tumor-feeding artery → necrosis

### 3. BCLC Stage C (Advanced Stage)

- **Systemic therapy**
  - **First-line**:
    - `Atezolizumab + bevacizumab` (preferred)
    - `Sorafenib` or `Lenvatinib`
  - **Second-line**:
    - `Regorafenib`, `Cabozantinib`, Immunotherapy (`nivolumab`)

### 4. BCLC Stage D (End-Stage)

- **Best supportive care**
  - Symptom control
  - Management of hepatic decompensation and encephalopathy

## Surgical Management

### Indications for Liver Resection

- Single lesion
- Preserved liver function (Child-Pugh A)
- Absence of significant portal hypertension
- No extrahepatic spread or major vascular invasion

### Preoperative Preparation

- Liver function assessment (Child-Pugh, ICG clearance)
- Cardiopulmonary evaluation
- Imaging for staging
- Nutritional support

### Surgical Procedures

- **Anatomical resection** (e.g., segmentectomy, lobectomy)
- **Non-anatomical wedge resection**
- Laparoscopic vs open resection based on expertise and tumor location

### Post-op Complications

- Liver failure
- Bile leak
- Bleeding
- Infection
- Recurrence (common in 5 years)

## Complications of HCC

- Portal vein invasion → portal hypertension
- Tumor rupture → intraperitoneal hemorrhage
- Paraneoplastic syndromes (erythrocytosis, hypoglycemia)
- Metastasis (lungs, bone, lymph nodes)

## Prevention

- **HBV vaccination**
- **Antiviral treatment** for HBV/HCV
- Regular surveillance in cirrhotics (USG + AFP every 6 months)
